The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.

Clinical and Translational Fungal Working Group University of California San Diego La Jolla CA

Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases University Hospital Cologne Cologne Germany

Comenius University and National Cancer Institute Bratislava Slovakia

Croatian Cooperative Group for Hematological Diseases Zagreb Croatia

Departament de Medicina Universitat Autònoma de Barcelona Bellaterra Spain

Department 1 of Internal Medicine Excellence Center for Medical Mycology Faculty of Medicine and University Hospital Cologne Cologne Germany

Department of Clinical Hematology Montpellier University Hospital IGMM UMR1535 CNRS University of Montpellier Montpellier France

Department of Clinical Mycology Allergy and Immunology North Western State Medical University St Petersburg Russia

Department of Hematological Medicine Kings College Hospital National Health Service Foundation Trust London United Kingdom

Department of Hematology Vall d'Hebron Hospital Universitari Vall d'Hebron Istitute of Oncology Vall d'Hebron Barcelona Hospital Campus Barcelona Spain

Department of Infectious Diseases Karolinska University Hospital Stockholm Sweden

Department of Internal Medicine Hematology and Oncology Masaryk University Hospital Brno Brno Czech Republic

Department of Medicine and Surgery University of Insubria and Azienda Socio Sanitaria Territoriale Sette Laghi Ospedale di Circolo of Varese Varese Italy

Division of Hematology and Bone Marrow Transplantation Fondazione IRCCS Istituto Nazionale dei Tumori University of Milano Milan Italy

Division of Infectious Diseases and Global Public Health Department of Medicine University of California San Diego San Diego CA

Division of Infectious Diseases and Hospital Epidemiology Department of Clinical Research University and University Hospital of Basel Basel Switzerland

Division of Infectious Diseases Department of Internal Medicine Medical University of Graz Graz Austria

Faculty of Medicine University of Zagreb Zagreb Croatia

Fundacion Jimenez Díaz Madrid Spain

German Centre for Infection Research Partner Site Bonn Cologne Cologne Germany

Hematology and Stem Cell Transplant Unit IRCCS Regina Elena National Cancer Institute Rome Italy

Hematology IRCCS Fondazione Policlinico Universitario Agostino Gemelli Rome Italy; and

Hematology Università Cattolica del Sacro Cuore Rome Italy

Hôpital Saint Louis Assistance Publique Hôpitaux de Paris Paris France

Hospital Clinic Barcelona Spain

Hospital Universitario de Salamanca Salamanca Spain

Hospital Univesitario Virgen del Rocío Seville Spain

IRCCS Ospedale San Raffaele Milan Italy

Katholieke Universiteit Leuven Leuven Belgium

King's College Hospital London United Kingdom

La Paz University Hospital Madrid Spain

Service d'Hématologie Clinique et de Thérapie Cellulaire Hôpital Saint Antoine AP HP Unité Mixte de Recherche 938 Sorbonne Universitè Paris France

Stem Cell Transplant Center Azienda Ospedaliera Universitaria Città della Salute e della Scienza Turin Italy

University Hospital Centre Zagreb Zagreb Croatia

University of Cologne Faculty of Medicine and University Hospital Cologne Clinical Trials Centre Cologne Cologne Germany

University of Milan and Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

See more in PubMed

Guan WJ, Ni ZY, Hu Y, et al. ; China Medical Treatment Expert Group for Covid-19 . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720. PubMed PMC

Miyashita H, Mikami T, Chopra N, et al. . Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City. Ann Oncol. 2020;31(8):1088-1089. PubMed PMC

Passamonti F, Cattaneo C, Arcaini L, et al. . Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-e745. PubMed PMC

Mehta V, Goel S, Kabarriti R, et al. . Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov. 2020; 10(7):935-941. PubMed PMC

Malard F, Genthon A, Brissot E, et al. . COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020;55(11):2180-2184. PubMed PMC

Piñana JL, Martino R, García-García I, et al. ; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH) . Risk factors and outcome of COVID-19 in patients with hematological malignancies. Exp Hematol Oncol. 2020;9:21. PubMed PMC

Martín-Moro F, Marquet J, Piris M, et al. . Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190(1):e16-e20. PubMed PMC

Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. . COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020;34(9):2354-2363. PubMed PMC

Altuntas F, Ata N, Yigenoglu TN, et al. ; Turkish Ministry of Health, Hematology Scientific Working Group . COVID-19 in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2021;56(4):952-955. PubMed

Shah GL, DeWolf S, Lee YJ, et al. . Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020; 130(12):6656-6667. PubMed PMC

Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. PubMed PMC

Strati P, Varma A, Adkins S, et al. . Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2021;106(10):2667-2672. PubMed PMC

Salmanton-García J, Busca A, Cornely OA, et al. . EPICOVIDEHA: a ready-to use platform for epidemiological studies in hematological patients with COVID-19. HemaSphere. 2021;5(7):e612. PubMed PMC

Shah V, Ko Ko T, Zuckerman M, et al. . Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King’s College Hospital experience. Br J Haematol. 2020;190(5):e279-e282. PubMed PMC

Maia C, Martín-Sánchez E, Garcés JJ, et al. . Immunologic characterization of COVID-19 patients with hematological cancer. Haematologica. 2020;106(5):1457-1460. PubMed PMC

Vijenthira A, Gong IY, Fox TA, et al. . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-2892. PubMed PMC

Logue JM, Zucchetti E, Bachmeier CA, et al. . Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2020;106(4):978-986. PubMed PMC

Rivera DR, Peters S, Panagiotou OA, et al. . Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: a COVID-19 and cancer consortium (CCC19) cohort study. Cancer Discov. 2020;10(10):1514-1527. PubMed PMC

Ljungman P, de la Camara R, Mikulska M, et al. . COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021;35(10):2885-2894. PubMed PMC

Sharma A, Bhatt NS, St Martin A, et al. . Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study [published correction appears in Lancet Haematol. 2021;8(6):e393]. Lancet Haematol. 2021;8(3):e185-e193. PubMed PMC

Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey